Senzime’s Interim report January – March 2019
Financial information first quarter 2019
- Net sales amounts to KSEK 385 (7)
- Income after financial items amounts to KSEK -9,508 (-4,099)
- Earnings per share before dilution amounts to SEK -0.18 (-0.10)
The first quarter has been intense, and it is fantastic to see the beginning of a positive sales trend with new customers both in Spain, Switzerland and Sweden. We sold monitors to a number of major hospitals in Sweden during the first quarter, of which Akademiska Sjukhuset is one. The agreement with Vingmed will make it possible for us to meet the increased interest in Sweden and expand our offering to the other Nordic countries. With Vingmeds experience and professionalism, we have found a strong collaboration partner to increase sales in the Nordic region.
In Europe, we have focused on prioritized markets spending more time with end users. Senzime has collaborated with several anesthesiologists and surgeons attracted by the TetraGraph for its precision, user-friendliness and clinical potential. We also participated in an educational neuromuscular monitoring training session in London giving anesthesiologist the opportunity to learn more about the TetraGraph. The response from these sessions was very positive!
Another important milestone during the quarter was the re-submission of the TetraGraph application to the FDA where we expect approval during 2019. In parallel, a major effort is being made to prepare both strategically and practically for the launch in the USA which will follow immediately after clearance.
In Asia, our Japanese licensing partner is preparing for market launch of TetraGraph following regulatory approval in Japan expected after the summer 2019. Our distributor in Korea is also expecting regulatory approval during the year with estimated sales start end Q4.
We appreciate your support and look forward to share further news.
Uppsala in May 2019, Pia Renaudin, CEO of Senzime AB (publ)
For further information, please contact:
Pia Renaudin, verkställande direktör
Tel: +46 70-813 34 17, e-post: email@example.com
Jessica Roxhed, CFO
Tel: +46 703-94 94 98, e-mail: firstname.lastname@example.org
TO THE EDITORS
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA, +46(0)8-528 00 399 is Certified Adviser for Senzime. www.senzime.com
This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on May 8 2019, 13:00.